Department of Cardiology, Lund University, SE-221 85 Lund, Sweden
THE EXTRACELLULAR NUCLEOTIDES ATP, ADP, UTP, and UDP are potent growth factors for vascular smooth muscle cells (VSMC) by actions on P2Y receptors (7, 9, 14, 20). The growth-stimulating effects may be of importance in the development of atherosclerosis, neointima after balloon angioplasty, chronic vascular rejection after transplantation, and hypertension (3). In these processes a central mechanism is the change of the VSMC from a highly differentiated contractile phenotype into a proliferative, more fibroblast-like synthetic phenotype (18). Extracellular nucleotides have different effects depending on phenotype. In the contractile phenotype, ATP acts as an important stimulator of VSMC contraction. For example, knockout experiments have shown that the ATP receptor P2X1 contributes to 50% of the sympathetic vasoconstriction in mice (19). By contrast, in the synthetic phenotype, extracellular nucleotides contribute to the mitogenic response.
In the current article in focus (Ref. 8, see p. C449 in this issue), Hogarth et al. show that ATP has a dual concentration-dependent effect on the VSMC phenotype. Low ATP concentrations stimulate expression of genes specific for the contractile phenotype. High ATP concentrations cause a phenotypic shift from the contractile to the synthetic phenotype, and this shift is dependent on a transient activation of protein kinase A (PKA), which inhibits activation of a serum response factor (SRF). This previously unrecognized mechanism also appears to be responsible for the profound mitogenic effect of ATP.
Mitogenic Effects
In contrast to the previously documented inhibitory effect of the intracellular second messenger cAMP on VSMC mitogenesis (13), Hogarth et al. (8) report that ATP-mediated activation of PKA is necessary for a maximum stimulation of DNA synthesis. If the adenylyl cyclase activator forskolin and the -adrenergic agonist isoproterenol were used to induce a prolonged PKA stimulation, mitogenesis was inhibited. By contrast, transient PKA stimulation evoked by ATP not only stimulated mitogenesis but also appeared to be necessary for the maximum mitogenic effect. However, when the authors tried to mimic the transient PKA stimulation by brief stimulation with forskolin, this treatment resulted in loss of the inhibitory effect but did not stimulate DNA synthesis. Thus the positive role of PKA in ATP-induced DNA synthesis cannot be explained solely by the transient duration of PKA activity induced by the agonist. Hogarth et al. suggest that an ATP stimulation of the PKA substrate vasodilator-stimulated phosphoprotein (VASP) could be crucial, but further studies are needed to confirm this possibility.
Hogarth et al. (8) also found that ERK1/2 was stimulated at both low and high concentrations of ATP. Interestingly, ERK1/2 activation was not inhibited by a high-efficiency adenovirus-mediated expression of the PKA inhibitor protein kinase I (PKI), even though DNA synthesis in response to high ATP was inhibited. Thus ATP stimulation of ERK1/2 is not dependent on PKA activation. In contrast, both ERK1/2 and transient PKA stimulation were found to be crucial for the major DNA stimulation by high-dose ATP, but on its own, ERK1/2 phosphorylation was not sufficient. On the other hand, low-dose ATP stimulation of DNA synthesis was shown to be ERK1/2 dependent but PKA independent. Thus ERK1/2 is required, but not sufficient, for profound DNA synthesis.
VSMC Phenotype
The phenotypic shift is a central mechanism for smooth muscle cell participation in the development of vascular disease. The cells lose contractile proteins, start to produce growth factors and matrix, become less differentiated and more fibroblast-like, begin to migrate, and proliferate (18). In the article in focus, Hogarth et al. report that low concentrations of ATP stimulated the activity of SRF. SRF is implicated in the transcription of VSMC-specific genes. Low concentrations of ATP also stimulated expression of SM22 and SM--actin, which are proteins specific for the contractile phenotype. By using an adenovirus encoding a DNA binding-deficient SRF mutant with dominant negative properties, the authors confirm that stimulation of SM22 and SM-
-actin expression by low ATP concentration is mediated by SRF activation. High concentrations of ATP, on the other hand, inhibited both SRF activity and the expression of VSMC-specific proteins, indicating a conversion into a synthetic phenotype. This was dependent on the transient PKA activation described above.
Interestingly, the change from the contractile to the synthetic phenotype is also characterized by downregulation of the contractile P2X1 receptor and upregulation of mitogenic P2Y receptors (6, 17). The P2X1 receptor is specific for the contractile VSMC (1, 21). Among P2 receptors, that subtype has the highest expression in VSMC in the intact vessel wall, and its expression is lost during cell culture (6). Shear stress, which is known to release ATP (2), induces changes in VSMC that are similar to a shift toward a more synthetic phenotype (22). Furthermore, high concentrations of ATP upregulate the expression of the mitogenic P2Y receptors P2Y2 and P2Y6 (9, 11). Hogarth et al. (8) provide a possible mechanism for the observed ATP-induced upregulation of P2Y receptors via transient stimulation of cAMP and PKA with a subsequent decrease in SRF activity. This could explain the observed forskolin-induced upregulation of P2Y2 receptors (10). It will be of interest to test for direct evidence for the link between SRF and P2 receptor regulation.
P2 Receptor Pharmacology
Nucleotide receptor pharmacology is complex because of the large number of P2 receptor subtypes and the limited availability of selective antagonists (16). Hogarth et al. (8) thus used various agonists to help define the role of specific P2Y receptor subtypes in the responses they studied. They were able to show that ADP receptors do not mediate the transient PKA activation, thereby excluding P2Y1, P2Y12, and P2Y13 receptors. Because UTP stimulation of DNA synthesis was PKA dependent only to a small extent, this finding excluded P2Y2 and P2Y4 receptors. Such results are in agreement with results in previous studies in other cell types in which different cAMP activation pathways for ATP and UTP were described (15). Use of adenosine 5'-O-(3-thiotriphosphate) (ATPS), which is resistant to degradation, and lack of inhibitory effect of an adenosine antagonist excludes participation of adenosine receptors and also the recently cloned adenosine and AMP receptor P2Y15, which reportedly stimulates both inositol 1,4,5-trisphosphate (IP3) and cAMP (12). Thus, by exclusion of other possible ATP receptors, the evidence suggests involvement of the P2Y11 receptor (4). This receptor also stimulates both IP3 and cAMP, but the physiological role of this activation of multiple second messengers has not been clarified. In the VSMC, IP3 and cAMP usually have opposite roles: contraction vs. relaxation or growth stimulation vs. inhibition. The present study offers a possible physiological role in which specific activation of these second messengers may be synergistic and necessary for ATP stimulation of DNA stimulation and phenotype change.
Actions of the P2Y11 receptor have not been shown previously in VSMC. However, on the basis of mRNA quantification in human VSMC, P2Y11 and P2Y6 receptors are the next most highly expressed P2Y receptor subtypes after P2Y2 (21). Further studies are necessary to firmly establish that the effects described by Hogarth et al. (8) are mediated by P2Y11 receptors.
The current results link previous results together in a model for ATP regulation of the VSMC (Fig. 1). Low or high ATP concentrations may determine VSMC phenotype and proliferation. In a situation with intact endothelium, the VSMC is protected against high ATP concentrations by endothelial ectonucleotidases; the low concentrations of ATP maintain VSMC in a contractile phenotype. This is important because in this situation VSMC regulate tone by contracting in response to ATP released from sympathetic nerves (19). Endothelial denudation results in VSMC proliferation (Fig. 1B). This has previously been explained by other mechanisms, for example, loss of endothelial NO (5). The work of Hogarth et al. suggests a new mechanism, namely, that the loss of endothelial ectonucleotidases results in exposure of the VSMC to high ATP levels, stimulating both growth and a shift into a synthetic phenotype. The synthetic phenotype is both proliferative and causes increased matrix deposition, resulting in stenosis of the vessel. The present study by Hogarth et al. provides data suggesting that ATP-stimulated transient PKA activation mediating inhibition of SRF may have a central role in both these processes.
|
Address for reprint requests and other correspondence: D. Erlinge, Dept. of Cardiology, Lund Univ., SE-221 85 Lund, Sweden (E-mail: david.erlinge{at}kard.lu.se).
REFERENCES
1. Bo X, Sexton A, Xiang Z, Nori SL, and Burnstock G. Pharmacological and histochemical evidence for P2X receptors in human umbilical vessels. Eur J Pharmacol 353: 5965, 1998.[CrossRef][ISI][Medline]
2. Bodin P, Bailey D, and Burnstock G. Increased flow-induced ATP release from isolated vascular endothelial cells but not smooth muscle cells. Br J Pharmacol 103: 12031205, 1991.[Abstract]
3. Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol 22: 364373, 2002.
4. Communi D, Govaerts C, Parmentier M, and Boeynaems JM. Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J Biol Chem 272: 3196931973, 1997.
5. D'Souza FM, Sparks RL, Chen H, Kadowitz PJ, and Jeter JR Jr. Mechanism of eNOS gene transfer inhibition of vascular smooth muscle cell proliferation. Am J Physiol Cell Physiol 284: C191C199, 2003.
6. Erlinge D, Hou M, Webb TE, Barnard E, and Möller S. Phenotype changes of the vascular smooth muscle cell regulate P2 receptor expression as measured by quantitative RT-PCR. Biochem Biophys Res Commun 248: 864870, 1998.[CrossRef][ISI][Medline]
7. Erlinge D, Yoo H, Edvinsson L, Reis DJ, and Wahlestedt C. Mitogenic effects of ATP on vascular smooth muscle cells vs. other growth factors and sympathetic cotransmitters. Am J Physiol Heart Circ Physiol 265: H1089H1097, 1993.
8. Hogarth DK, Sandbo N, Taurin S, Kolenko V, Miano JM, and Dulin NO. Dual role of PKA in the phenotypic modulation of vascular smooth muscle cells by extracellular ATP. Am J Physiol Cell Physiol 287: C449C456, 2004.
9. Hou M, Harden TK, Kuhn CM, Baldetorp B, Lazarowski E, Pendergast W, Möller S, Edvinsson L, and Erlinge D. UDP acts as a growth factor for vascular smooth muscle cells by activation of P2Y6 receptors. Am J Physiol Heart Circ Physiol 282: H784H792, 2002.
10. Hou M, Möller S, Edvinsson L, and Erlinge D. Cytokines induce upregulation of vascular P2Y2-receptors and increase mitogenic responses to UTP and ATP. Arterioscler Thromb Vasc Biol 20: 20642069, 2000.
11. Hou M, Möller S, Edvinsson L, and Erlinge D. MAPKK-dependent growth factor induced upregulation of P2Y2-receptors in vascular smooth muscle cells. Biochem Biophys Res Commun 258: 648652, 1999.[CrossRef][ISI][Medline]
12. Inbe H, Watanabe S, Miyawaki M, Tanabe E, and Encinas JA. Identification and characterization of a cell-surface receptor, P2Y15, for AMP and adenosine. J Biol Chem 279: 1979019799, 2004. First published March 4, 2004; 10.1074/jbc.M400360200.
13. Ito C, Kusano E, Furukawa Y, Yamamoto H, Takeda S, Akimoto T, Iimura O, Ando Y, Asano Ito C Y, Kusano E, Furukawa Y, Yamamoto H, Takeda S, Akimoto T, Iimura O, and Ando Y. Modulation of the erythropoietin-induced proliferative pathway by cAMP in vascular smooth muscle cells. Am J Physiol Cell Physiol 283: C1715C1721, 2002.
14. Malam-Souley R, Campan M, Gadeau A, and Desgranges C. Exogenous ATP induces a limited cell cycle progression of arterial smooth muscle cells. Am J Physiol Cell Physiol 264: C783C788, 1993.
15. Post SR, Rump C, Zambon A, Hughes RJ, Buda MD, Jacobson P, Kao CC, and Insel P. ATP activates cAMP production via multiple purinergic receptors in MDCK-D1 epithelial cells. J Biol Chem 273: 2309323097, 1998.
16. Ralevic V and Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 50: 413492, 1998.
17. Seye CI, Gadeau AP, Daret D, Dupuch F, Alzieu P, Capron L, and Desgranges C. Overexpression of the P2Y2 purinoceptor in intimal lesions of the rat aorta. Arterioscler Thromb Vasc Biol 17: 36023610, 1997.
18. Thyberg J. Differentiated properties and proliferation of arterial smooth muscle cells in culture. Int Rev Cytol 169: 183265, 1996.[ISI][Medline]
19. Vial C and Evans RJ. P2X1 receptor-deficient mice establish the native P2X receptor and a P2Y6-like receptor in arteries. Mol Pharmacol 62: 14381445, 2002.
20. Wang DJ, Huang NN, and Heppel LA. Extracellular ATP and ADP stimulate proliferation of porcine aortic smooth muscle cells. J Cell Physiol 153: 221233, 1992.[ISI][Medline]
21. Wang L, Karlsson L, Moses S, Hultgårdh-Nilsson A, Andersson M, Borna C, Gudbjartsson T, Jern S, and Erlinge D. Specific P2 receptor expression in human vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 40: 841853, 2002.[CrossRef][ISI][Medline]
22. Wang L, Andersson M, Karlsson L, Watson MA, Cousens D, Jern S, and Erlinge D. Increase in mitogenic and decrease in contractile P2 receptors by fluid shear stress in intact human conduit vessels. Arterioscler Thromb Vasc Biol 23: 13701376, 2003.